Table 1 Baseline clinical characteristics of patients with systemic sclerosis
|  | CD34-selected (n = 11) | Unmanipulated (n = 8) | p value |
|---|---|---|---|
Age, years | 52.3 ± 7.9 | 55.8 ± 5.0 | 0.29 |
Female, n (%) | 8 (73) | 7 (88) | 0.60 |
Smokers, n (%) | 4 (36) | 4 (50) | 0.66 |
Disease duration, median (IQR), years | 1.4 (1.2–2.8) | 1.2 (0.9–1.7) | 0.18 |
DcSSc with severe skin sclerosis, n (%) | 9 (82) | 6 (75) | 1.00 |
Modified Rodnan skin score | 21.5 ± 9.6 | 22.9 ± 14.0 | 0.81 |
Interstitial pneumonia, n (%) | 11 (100) | 6 (75) | 0.16 |
Percent predicted FVC | 63.1 ± 14.7 | 83.1 ± 17.3 | 0.01 |
Percent predicted DLCO | 46.4 ± 17.1 | 49.8 ± 22.9 | 0.71 |
LVEF | 70.1 ± 8.0 | 74.5 ± 6.8 | 0.29 |
Anti-Scl70 antibody positive, n (%) | 9 (82) | 4 (50) | 0.32 |
Previous treatment, n (%) | 10 (91) | 5 (62.5) | 0.26 |
Corticosteroids, n (%) | 10 (91) | 5 (62.5) | 0.26 |
Cyclophosphamide, n (%) | 4 (36) | 3 (38) | 1.00 |
Tacrolimus or cyclosporine, n (%) | 3 (27) | 2 (35) | 1.00 |